Utilizing shRNA to downregulate LAMP1 in B16F10 mouse melanoma cells can attenuate the induction of matrix metalloproteinase (MMP9) expression by the p38 MAPK signaling pathway activated by galectin-3 and polyN-acetyllactosamine (polyLacNAc) (25). Here, MMP9 is linked to melanoma.